{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:07:38Z","timestamp":1793210858155,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007472","name":"University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.msard.2021.102942","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T22:55:13Z","timestamp":1617922513000},"page":"102942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Use of anti-TNF-\u03b1 therapy in Crohn's disease is associated with increased incidence of multiple sclerosis"],"prefix":"10.1016","volume":"51","author":[{"given":"Jagannadha","family":"Avasarala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Guduru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-9748","authenticated-orcid":false,"given":"Christopher J.","family":"McLouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Wilburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Talbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9452-6190","authenticated-orcid":false,"given":"Brent S.","family":"Sokola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2021.102942_bib0001","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The lenercept multiple sclerosis study group and The University of British Columbia MS\/MRI analysis group","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102942_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819827692","article-title":"Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010","volume":"12","author":"Aniwan","year":"2019","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"3","key":"10.1016\/j.msard.2021.102942_bib0003","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrneurol.2011.1","article-title":"Monoclonal antibody therapy-associated neurological disorders","volume":"7","author":"Bosch","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2021.102942_bib0004","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.msard.2021.102942_bib0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri3834","article-title":"Regulation of tumour necrosis factor signalling: live or let die","volume":"15","author":"Brenner","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.msard.2021.102942_bib0006","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awy131","article-title":"The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics","volume":"141","author":"Camara-Lemarroy","year":"2018","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2021.102942_bib0007","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1186\/ar3397","article-title":"Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label","volume":"13","author":"Diaz-Lagares","year":"2011","journal-title":"Arthr. Res. Ther."},{"key":"10.1016\/j.msard.2021.102942_bib0008","article-title":"Th17 cells pathways in multiple sclerosis and neuromyelitis optica spectrum disorders: pathophysiological and therapeutic implications","author":"Dos Passos","year":"2016","journal-title":"Mediat. Inflamm."},{"issue":"9","key":"10.1016\/j.msard.2021.102942_bib0009","first-page":"416","article-title":"Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nature clinical practice","volume":"2","author":"Fasano","year":"2005","journal-title":"Gastroenterol. Hepatol."},{"issue":"8954","key":"10.1016\/j.msard.2021.102942_bib0010","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0140-6736(95)90013-6","article-title":"Focal white-matter lesions in brain of patients with inflammatory bowel disease","volume":"345","author":"Geissler","year":"1995","journal-title":"Lancet (Lond. Engl.)"},{"issue":"3","key":"10.1016\/j.msard.2021.102942_bib0011","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1053\/j.gastro.2005.06.022","article-title":"Increased risk for demyelinating diseases in patients with inflammatory bowel disease","volume":"129","author":"Gupta","year":"2005","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.msard.2021.102942_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/qjmed\/hcr237","article-title":"Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease","volume":"107","author":"Hare","year":"2014","journal-title":"QJM : Month. J. Asso. Phys."},{"issue":"3","key":"10.1016\/j.msard.2021.102942_bib0013","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1586\/1744666X.2014.885381","article-title":"Inflammatory bowel disease and demyelination: more than just a coincidence?","volume":"10","author":"Katsanos","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"12","key":"10.1016\/j.msard.2021.102942_bib0014","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1136\/gutjnl-2011-301574","article-title":"Geographical variation and incidence of inflammatory bowel disease among US women","volume":"61","author":"Khalili","year":"2012","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.msard.2021.102942_bib0015","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4065\/75.8.802","article-title":"Concurrence of inflammatory bowel disease and multiple sclerosis","volume":"75","author":"Kimura","year":"2000","journal-title":"Mayo Clin. Proceed."},{"issue":"2","key":"10.1016\/j.msard.2021.102942_bib0016","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00415-016-8340-8","article-title":"Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis","volume":"264","author":"Kosmidou","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.102942_bib0017","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/979258","article-title":"Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity","author":"Kunz","year":"2009","journal-title":"Mediat. Inflamm."},{"issue":"7 Pt 2","key":"10.1016\/j.msard.2021.102942_bib0018","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1212\/WNL.30.7_Part_2.61","article-title":"Epidemiologic contributions to multiple sclerosis: an overview","volume":"30","author":"Kurtzke","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102942_bib0019","doi-asserted-by":"crossref","first-page":"h2809","DOI":"10.1136\/bmj.h2809","article-title":"Association between tumor necrosis factor-\u03b1 inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","volume":"350","author":"Andersen","year":"2015","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.msard.2021.102942_bib0020","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/1352458510369146","article-title":"Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study","volume":"16","author":"Langer-Gould","year":"2010","journal-title":"Mult. Scler. (Houndmills, Basingstoke, England)"},{"issue":"46","key":"10.1016\/j.msard.2021.102942_bib0021","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.3748\/wjg.15.5784","article-title":"Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease","volume":"15","author":"Liu","year":"2009","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.msard.2021.102942_bib0022","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/1352458514564490","article-title":"A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler. (Houndmills, Basingstoke, Engl.)"},{"issue":"12","key":"10.1016\/j.msard.2021.102942_bib0023","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthr. Rheum"},{"issue":"9","key":"10.1016\/j.msard.2021.102942_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106335","article-title":"Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells","volume":"9","author":"Nouri","year":"2014","journal-title":"PloS one"},{"issue":"11","key":"10.1016\/j.msard.2021.102942_bib0025","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)","volume":"16","author":"Perez-De-Lis","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"8","key":"10.1016\/j.msard.2021.102942_bib0026","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","article-title":"Anti-Tumor necrosis factor therapy and incidence of parkinson disease among patients with inflammatory bowel disease","volume":"75","author":"Peter","year":"2018","journal-title":"JAMA Neurol."},{"issue":"8297","key":"10.1016\/j.msard.2021.102942_bib0027","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(82)90629-8","article-title":"Association of ulcerative colitis with multiple sclerosis","volume":"2","author":"Rang","year":"1982","journal-title":"Lancet (Lond., Engl.)"},{"issue":"7359","key":"10.1016\/j.msard.2021.102942_bib0028","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"Sawcer","year":"2011","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.msard.2021.102942_bib0029","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2006.066787","article-title":"Optic neuritis occurring with anti-tumour necrosis factor alpha therapy","volume":"66","author":"Simsek","year":"2007","journal-title":"Ann. Rheumatic Dis."},{"issue":"6","key":"10.1016\/j.msard.2021.102942_bib0030","first-page":"1548","article-title":"Anti-tumor necrosis factor alpha-associated multiple sclerosis","volume":"26","author":"Titelbaum","year":"2005","journal-title":"AJNR. Am. J. Neuroradiol."},{"issue":"6","key":"10.1016\/j.msard.2021.102942_bib0031","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2021.102942_bib0032","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1177\/1352458516679894","article-title":"Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans","volume":"23","author":"Ventura","year":"2017","journal-title":"Mult. Scler. (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.msard.2021.102942_bib0033","unstructured":"Yapali, S., over Hamzaoglu, H.J.A.o.g., 2007. Anti-TNF treatment in inflammatory bowel disease."},{"issue":"8","key":"10.1016\/j.msard.2021.102942_bib0034","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458513515081","article-title":"Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease","volume":"20","author":"Zephir","year":"2014","journal-title":"Mult. Scler. (Houndmills, Basingstoke, England)"},{"issue":"10","key":"10.1016\/j.msard.2021.102942_bib0035","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00330-014-3242-6","article-title":"Brain involvement in patients with inflammatory bowel disease: a voxel-based morphometry and diffusion tensor imaging study","volume":"24","author":"Zikou","year":"2014","journal-title":"Eur. Radiol."},{"issue":"3","key":"10.1016\/j.msard.2021.102942_bib0036","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.semarthrit.2011.05.003","article-title":"Demyelinating disease in patients treated with with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review","volume":"41","author":"Fernandez-Espartero","year":"2011","journal-title":"Seminars Arthr. Rheumatism"},{"issue":"3","key":"10.1016\/j.msard.2021.102942_bib0037","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrneurol.2011.1","article-title":"Monoclonal antibody therapy-associated neurologic disorders","volume":"7","author":"Bosch","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2021.102942_bib0038","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 Blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:54:26Z","timestamp":1761900866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":38,"alternative-id":["S2211034821002091"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102942","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of anti-TNF-\u03b1 therapy in Crohn's disease is associated with increased incidence of multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102942"}}